Alnylam Pharmaceuticals Inc (ALNY)vsAurinia Pharmaceuticals Inc (AUPH)
ALNY
Alnylam Pharmaceuticals Inc
$284.84
-3.46%
HEALTHCARE · Cap: $39.39B
AUPH
Aurinia Pharmaceuticals Inc
$15.72
+3.22%
HEALTHCARE · Cap: $2.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 1337% more annual revenue ($4.29B vs $298.30M). AUPH leads profitability with a 100.0% profit margin vs 12.6%. AUPH trades at a lower P/E of 7.3x. AUPH earns a higher WallStSmart Score of 69/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
AUPH
Strong Buy69
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.6%
Fair Value
$2410.60
Current Price
$284.84
$2125.76 discount
Intrinsic value data unavailable for AUPH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 90 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Attractively priced relative to earnings
Every $100 of equity generates 65 in profit
Keeps 100 of every $100 in revenue as profit
Strong operational efficiency at 53.3%
Earnings expanding 56.3% YoY
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 35.3x book value
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : AUPH
The strongest argument for AUPH centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 100.0% and operating margin at 53.3%. Revenue growth of 24.4% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 74.1x leaves little room for execution misses.
Bear Case : AUPH
The primary concerns for AUPH are Altman Z-Score.
Key Dynamics to Monitor
AUPH carries more volatility with a beta of 1.45 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AUPH scores higher overall (69/100 vs 65/100), backed by strong 100.0% margins and 24.4% revenue growth. ALNY offers better value entry with a 86.6% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Aurinia Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?